• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Incannex Front and Centre for ASX Cannabis Rally, Shares Up (ASX:IHL)

Like 0

By Lachlann Tierney, Thursday, 11 February 2021

Medicinal cannabinoid company Incannex Healthcare Ltd [ASX:IHL] is one of the leading stocks. At time of writing the IHL share price is up 12.82%, or 2.5 cents, to trade at 22 cents per share, on news that the company is seeking to dual list on an American exchange...

Medicinal cannabinoid company Incannex Healthcare Ltd [ASX:IHL] is one of the leading stocks of the ASX’s recent cannabis resurgence.

At time of writing the IHL share price is up 12.82%, or 2.5 cents, to trade at 22 cents per share, on news that the company is seeking to dual list on an American exchange.

ASX IHL Share Price Chart

Source: Trading View

Despite a rise in healthcare stocks during the height of the pandemic last year, cannabis stocks were either dumped or ignored due to investors’ small appetite for risk.

This year, however, a rally reminiscent of 2018 could be on the cards as cannabis stocks globally began to rally in December.

Incannex seeks global exposure

IHL announced today that it is undergoing preliminary efforts in order to dual list its securities on a US main market, such as the NYSE or Nasdaq.

IHL has entered into a binding consulting agreement with EAS Advisors to facilitate introductions to US banks and institutions with the aim of dual listing.

Essentially this preliminary work entails introductions to equity research providers in order to secure analyst coverage.

The goal of which is to generate global investor awareness with potential strategic investors to help secure better funding.

And to assist with financial modelling, presentation preparation, and external data room maintenance.

Three Undervalued Aussie Pot Stocks to Watch. Click Here to Learn More.

CEO and Managing Director Joel Latham commented on the company’s decision:

‘We have made this decision because of deep investor interest and corporate activity in both cannabinoid-based pharmaceuticals and psychedelic therapeutic endeavours in North America. We’re delighted to be working with the team at EAS, which has an excellent track record of growing international awareness for ASX companies.’

Why the IHL share price action?

If you’re wondering why the share price would react to IHL merely announcing they have hired someone to help them make introductions, think of it this way:

Many US states have legalised cannabis, and the country is well on its way to decriminalising the drug.

Meaning the US industry has had far more time to mature and attract investors compared to Australia.

Which means there is more money for funding.

And more opportunities for growth.

Now, dual listing can be an expensive operation and can demand significant ongoing listing expenses.

However, I suspect part of the share price action today is a subtle nod to the outlook of IHL’s shares.

The cannabis company said as part of the term of its contract with EAS it would release two tranches of 10 million options exercisable at 20 and 25 cents per security.

Which could be a nice little vote of self-confidence.

If you’re on the lookout for other cannabis stocks poised to rise during a renewed Aussie cannabis boom, then check out our top three ASX-listed pot stocks in 2021. Click here to download the free report.

Regards,

Lachlann Tierney,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Don’t Get Swept Up By the Herd: Bulls & Bears in an Age of Social Media
    By Charlie Ormond

    Markets have always reflected this chaotic behaviour, but today’s markets operate in an environment fundamentally transformed by social media.

  • The latest Closing Bell is available now
    By Callum Newman

    Tune in today to watch the latest Closing Bell podcast with Murray Dawes. We discuss gold, oil, real estate…plus a stock to watch. Tune in now!

  • Thorium: One Step Closer to China’s Energy Fortress
    By James Cooper

    Forget AI, the biggest breakthrough of this century will revolve around ENERGY. And the commercialisation of Thorium reactors could be at the heart. Read on to find out why China could be about to make history.

Primary Sidebar

Latest Articles

  • Don’t Get Swept Up By the Herd: Bulls & Bears in an Age of Social Media
  • The latest Closing Bell is available now
  • Thorium: One Step Closer to China’s Energy Fortress
  • The famous yield curve: buy or sell signal? You decide…
  • How Australians voted for a great wealth redistribution

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988